Seres Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Seres Therapeutics reported a net loss for the period and highlighted substantial doubt regarding its ability to continue as a going concern, necessitating additional funding.
NASDAQ
Seres Therapeutics filed its Q1 2026 Form 10-Q, detailing a net loss of $19.9 million and highlighting ongoing efforts to secure additional funding while pausing investment in the SER-155 Phase 2 study.
NASDAQ
Seres Therapeutics reports Q3 2025 net income driven by VOWST sale proceeds, but faces substantial doubt about its ability to continue as a going concern beyond Q2 2026 without additional funding.
NASDAQ
Seres Therapeutics reported a net income for the first half of 2025 driven by the VOWST business sale, but faces substantial doubt about its ability to continue as a going concern without additional funding by Q1 2026.
NASDAQ
10-Q: Seres Therapeutics Reports Q1 2025 Results, Highlights SER-155 Development and Partnership Efforts
Seres Therapeutics reports a net income of $32.7 million for Q1 2025, driven by the sale of its VOWST business, while focusing on the development of SER-155 and seeking strategic partnerships.
NASDAQ
Seres Therapeutics finalized the sale of its VOWST business to Nestl Health Science, shifting its focus to advancing its pipeline, particularly SER-155.
NASDAQ
Seres Therapeutics has agreed to sell its VOWST business to Nestl for up to $335 million plus future royalties, while also reporting a net loss of $73 million for the first half of 2024 and raising concerns about its ability to continue as a going concern.
NASDAQ
Seres Therapeutics reports a net loss of $40.1 million for Q1 2024 and acknowledges substantial doubt about its ability to continue as a going concern, despite ongoing commercialization of VOWST and progress in SER-155 clinical trials.